Accessing Amivantamab in China — Eligibility Explained
Amivantamab is an internationally approved targeted therapy for certain non-small cell lung cancers. In China it may be accessible to eligible patients through the Hainan Boao Lecheng special-import pathway, subject to clinical review.
What is the Boao Lecheng pathway?
The Hainan Boao Lecheng International Medical Tourism Pilot Zone allows selected medicines already approved abroad to be used in-zone ahead of mainland registration.
Who may be eligible?
Eligibility for any specific patient is determined solely by clinical assessment at the treating hospital, based on diagnosis, prior treatment, and biomarker testing.
| Step | What happens |
|---|---|
| 1 | Medical pre-screening |
| 2 | Clinical eligibility review |
| 3 | In-zone treatment planning |
Frequently asked questions
Is amivantamab always available?
No. Availability and eligibility depend on clinical review and pilot-zone import approval.
This article was produced with AI assistance and reviewed against Uwell Cloud editorial and compliance standards.
Important medical & regulatory notice. This page is for general information only and is not medical advice, a diagnosis, a prescription, or a guarantee of any outcome. Treatment availability and eligibility for any individual are determined solely by clinical review at the treating hospital. Uwell Cloud is an international medical-travel coordinator, not the treating provider.
← All insights